ArticleBMC cancer2025
Stereotactic re-irradiation for lymph node recurrence of breast cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeBetween 5% and 20% of patients with breast cancer (BC) experience locoregional recurrence (LRR). Managing LRR in previously irradiated areas is particularly challenging. We evaluated the toxicity and efficacy of stereotactic body re-irradiation in this context. MATERIALS AND
methodsThis was a single-center retrospective study conducted between January 2009 and December 2022. It included patients who underwent stereotactic re-irradiation for LRR of BC. We assessed toxicity, local control (LC), progression-free survival (PFS), and overall survival (OS).
resultsEighteen patients were included. The median dose of the initial radiotherapy (RT) was 60 Gy (range: 50–68 Gy). Recurrences occurred in level I-II nodes (n = 10), internal mammary nodes (IMN; n = 4), level III (n = 2), and level IV (n = 2). The median interval between the two irradiations was 11 years (range: 1–24 years). The most commonly used stereotactic re-irradiation regimens were 6 × 6 Gy and 3 × 9 Gy. Median D50% to the GTV and PTV was 36.9 Gy (32–41.8 Gy) and 35.7 (30.2–40.6 Gy), respectively. The D0.035 cc to the brachial plexus was 11.2 Gy (range, 4–33.6 Gy). With a median follow-up of 4.5 years from the start of SRT (IQR: 2.0‒7.5), no radiation-induced brachial plexopathy was observed. The cumulative incidence of locoregional recurrence was 56.4% (95%CI: 30.8–75.6) at 2 years. The 5-year overall survival (OS) rate was 75.5% (95CI: 39.7–91.8), with most deaths attributed to distant metastases.
conclusionStereotactic re-irradiation is a well-tolerated treatment option for LRR in breast cancer. Particular care should be taken to minimize the dose to the brachial plexus. While local control is acceptable, the risk of further regional recurrence remains high.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.